Ibrahim, Myla M.
HRN: 28-87-50 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/18/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
04/18/2024
04/25/2024
IV
2.2g
Q 6 Hours
T/C Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes